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Abstract
The catalytic activity of L-aspartate a-decarboxylase (ADC) is essential for the growth of several micro-organisms, including
Mycobacterium tuberculosis (Mtb), and has triggered efforts for the development of pharmaceutically active compounds
against tuberculosis. The present study is a continuation of our recent chemoinformatics-based design approach for
identifying potential drug-like inhibitors against MtbADC. We report an NMR-based protocol that allows label-free and
direct monitoring of enzymatic conversion, which we have combined with a systematic testing of reported and newly
identified potential inhibitors against MtbADC. Quantification of enzymatic conversion in the absence and presence of
inhibitors allowed for a relative measure of the inhibitory effect (krel). Among the newly identified compounds, D-tartrate, L-
tartrate, and 2,4-dihydroxypyrimidine-5-carboxylate were found to inhibit the enzyme with krel values of 0.36, 0.38, and 0.54,
respectively. In addition to the identification of potential building blocks for the development of therapeutic agents, the
current study highlights the importance of electrostatic interactions governing enzyme-inhibitor binding.
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Introduction
L-aspartate a-decarboxylase (ADC, EC 4.1.1.11), encoded by
the E. coli panD gene, is an enzyme responsible for the conversion
of L-aspartate to b-alanine and its activity has been shown to be
crucial for the growth of several microorganisms, including
Mycobacterium tuberculosis (Mtb) [1–3]. In short, formation of b-
alanine allows the synthesis of panthotenate (vitamin B5), the
precursor of coenzyme A (CoA), which in turn plays an essential
role in the metabolism and biosynthesis of fatty acids. The
complex lipidoglycans found in the Mtb cell wall are therefore
crucial for the intracellular replication, persistence, and virulence
of the bacterium [4–6]. Impairing the pantothenate pathway by
suppressing b-alanine formation has been shown to result in a
significant decline in Mtb virulence [7,8], which has motivated us
to consider ADC as a potential target for therapeutic intervention
against tuberculosis.
Recently, we have engaged in a chemoinformatics-based
approach to identify potential drug-like inhibitors by structure-
based virtual screening, which led to 28 lead molecules [9]. The
purpose of our present investigation is to experimentally test a
representative subset of the identified targets and contrast them
with several compounds, which in part have been previously
shown to be active in inhibition experiments [8,10,11]. Existing
assays for ADC involve derivatization and separation steps
[12,13], radioactive labeling [1,10] and laborious manometric
quantification of the carbon dioxide released as a reaction by-
product [14]. Extending our ongoing efforts in the design of
enzyme assays [15,16], including decarboxylase assays [17], we
report a novel but simple 1H NMR protocol for monitoring ADC
activity, which not only allows for direct structural information on
the enzymatic reaction to be obtained and progress curves to be
taken, but also serves as a convenient tool for inhibitor screening.
Materials and Methods
Inhibitors
The previously reported and newly identified compounds that
were tested in the present study for inhibitory effect against ADC
are shown in Fig. 1. Oxaloacetate (K1), DL-threo-b-hydroxyaspar-
tate (K2), L-glutamate (K3), L-cysteic acid (K4), succinate (K5), L-
serine (K6), and D-serine (K7) had been tested previously, while D-
tartrate (I1, ZINC00895296), L-tartrate (I2, ZINC00895301), 2,4-
dihydroxypyrimidine-5-carboxylate (I3, ZINC00901606), D-taga-
tose (I4, ZINC03830878), (4S)-1,3-thiazolidin-3-ium-4-carboxyl-
ate (I5, ZINC00967474), a-D-arabinopyranose (I6,
ZINC03606295), and 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one
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(I7, ZINC05177572) were tested for the first time, stimulated by
the hits recently identified in the chemoinformatics study [9]. The
compounds were purchased from Sigma-Aldrich, Germany (K1–
K7 and I1–I4), or from Labotest KG, Germany (I5–I7), in the
highest commercially available purity (.97%).
Protein preparation
Mycobacterium tuberculosis L-aspartate a-decarboxylase (MtbADC)
was overexpressed with a C-terminal 6xHis tag in E. coli and
purified as the cleaved tetrameric form by Ni2+-NTA affinity and
gel filtration chromatography as described previously [2,6]. The
protein was further dialyzed against 10 mM Tris, pH 7.5.
Enzyme assays
The enzymatic reactions were carried out in D2O (Sigma-
Aldrich) using 1 mM L-aspartic acid as substrate in the absence or
presence of 1 mM inhibitor. The reactions were initiated by
addition of enzyme (2.83 mM, as determined by using an
extinction coefficient e280 = 6400 M
21cm21 [2] and measured
on a Varian Cary 4000 UV-Vis spectrophotometer. The
enzymatic activity was followed by 1H NMR using a Jeol JNM-
ECX 400 spectrometer.
Results and Discussion
Enzyme assays
Before proceeding to inhibitor screening, a convenient assay for
monitoring the ADC activity was established. Since during an
enzymatic transformation, structural changes, which may be
detected by differences in spectra of the substrate and product of
the reaction, occur almost inevitably [18,19], we opted for NMR
spectroscopy as the technique of choice. Therefore, we validated a
simple protocol using 1H NMR for monitoring the enzymatic
depletion of L-aspartate and concomitant formation of b-alanine.
The advantage of 1H NMR is that the technique is label-free and
allows direct monitoring. To this end, the conversion of 1 mM L-
aspartate in the presence of 3 mM ADC could be conveniently
followed as shown in Fig. 2. L-aspartate shows two resonances, in a
1:2 ratio (Fig. 2a). Upon addition of ADC, the signals
corresponding to the product start to emerge and intensify with
time while those of the substrate L-aspartate diminish and
eventually completely disappear (Fig. 2 b–e). Note that, based on
its structure, one would also expect two different 1H NMR peaks
for b-alanine (this was confirmed by taking a spectrum for the
commercial analyte). However, only the signals corresponding to
the protons adjacent to the carboxylate group could be quantified
in the course of the enzymatic reaction (at approximately
d=2.44 ppm). This is a consequence of the fact that the reaction
is carried out in D2O, and, therefore, the newly acquired b-alanine
hydrogen is, in fact, a deuterium atom. This is also in line with
both the broadness of the signal identified at approximately
d=3.04 ppm and the splitting pattern (a doublet) of the upfield-
shifted protons.The assay was optimized with respect to substrate
and enzyme concentrations, such that the conversion rate was
directly proportional to the enzyme concentration.
Accordingly, the depletion of the L-aspartate substrate and the
concomitant formation of b-alanine could be readily detected and,
upon integration, also accurately quantified. This has finally
allowed us to extract a kinetic profile of the enzyme in the absence
of inhibitor (empty and filled circles in Fig. 3), which does not only
depict a time-resolved monitoring of b-alanine formation as a
result of the enzymatic activity, but also serves as a reference for
subsequent inhibition studies (for instance, D-tartrate, empty and
filled squares in Fig. 3). Since it is desirable to work in the linear
region of the enzyme kinetic trace, we have used in our study 50%
conversion in the absence of inhibitor as a reference point, which
was achieved at t=30–40 min, depending on the enzyme batch
used.
Inhibitors selected
Despite the relevance of ADC as a drug target, only a relatively
small number of compounds have been reported to inhibit its
activity [10]. Among these previously identified inhibitors, we have
selected seven (K1–K7, Fig. 1), which we also tested experimen-
tally. The inhibitory effects of these molecules have been
previously quantified on E. coli ADC and inhibition constants
have been determined in the mM range [10].
In our recent study [9], 336,761 molecules from three public
databases have been targeted: the Maybridge (14,400 molecules),
the Zinc (including the National Cancer Institute, 316,181
molecules), and the United States of America Foods and Drug
Figure 1. Chemical structures of known inhibitors against ADC
(K1–K7) and computationally identified potential inhibitors
obtained via virtual screening (I1–I7).
doi:10.1371/journal.pone.0045947.g001
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Administration approved drugs database (3,180 molecules). A
high-throughput virtual screening, based on the interaction of
these compounds with the active site residues of the enzyme by
using a stronger binding affinity as compared to that of the
MtbADC:fumarate reference (24.2 kcal/mol) as a positive
criterion, led to the identification of 28 lead molecules. Herein,
we tested a representative and commercially accessible subset of
the positive hits (I1–I7, Fig. 1) and compared them under identical
experimental conditions to the known ADC inhibitors. Apart from
excluding cross-reactivity towards other pyruvoyl-dependent
enzymes, all newly tested ligands were selected by ensuring a
direct interaction with the well-conserved Arg54, whose role in
substrate specificity has already been acknowledged [20,21].
Inhibition studies
The enzymatic reactions for inhibitor screening were performed
in the presence of 1 mM potential inhibitor, similar to the
concentrations employed in previous enzymatic assays [10,11].
The enzymatic conversion at specific reaction times in the absence
and presence of inhibitor was compared and defined as krel, which
we used as a relative measure of inhibition efficiency (vide infra).
The results are compiled in Table 1. As expected from literature
data [10], mM inhibitor concentrations were required to induce a
significant inhibitory effect for most compounds, including the
newly identified ones. Since all compounds reported by William-
son and Brown act as competitive inhibitors against ADC [10], it
did not come as a surprise that the most effective ones were those
containing two carboxylate moieties (K1–K5), which are consid-
ered to be structural analogues to the natural substrate L-
aspartate. In fact, b-hydroxyaspartate (K2), meso-diaminosuccinate
(herein we tested succinate, K5), and cysteic acid (K4) have been
amongst the first compounds shown to effect the pantothenate
pathway [22,23]. A recent study, where MALDI-TOF mass
spectrometry has been employed as a screening methodology for
identifying compounds that bind to ADC, has in fact revealed that
only a few homologs of L-aspartate, such as L-glutamate (K3), can
penetrate into the active site of the enzyme [11]. The only two
dicarboxylate exceptions constitute the two amino acids L- and D-
Figure 2. Selected 1H NMR spectra of 1 mM L-aspartate a) before and b)–e) 10–80 min after addition of 3 mM ADC in D2O at 25uC. The diminishing
signals of L-aspartate and the emerging ones of those corresponding to b-alanine permitted a direct monitoring of the enzymatic transformation and
integration of the proton signals allowed for a kinetic profiling of the reaction (cf. Fig. 3).
doi:10.1371/journal.pone.0045947.g002
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serine (K6 and K7), respectively, which have also been reported to
inhibit b-alanine synthesis [10,24]. Particularly, D-serine had been
found to be 4.5 times more potent than its L-enantiomer (Ki = 0.16
vs. 0.73 mM, respectively) [10]. In our direct label-free assays,
neither K6 nor K7 showed a considerable inhibitory effect towards
ADC activity. However, among all known inhibitors, the most
surprising effect was exhibited by oxaloacetate K1, in the presence
of which no biocatalytic activity was detected at all (krel = 0).
Complementing the chemoinformatics-based approach, our
experimental data show that most molecules possessing a sizable
inhibitory potential are, similar to those previously reported [10],
anionic in nature. D-tartrate (I1, krel = 0.36) was found to be a
strong inhibitor, followed by the pyrimidine derivative I3
(krel = 0.54), whose presence reduced the ADC activity by
approximately 50%. Presumably, the smaller effect of I3, when
compared to I1, is due to a weaker electrostatic binding with the
enzyme active site. Surprisingly, D-tagatose (I4), which is a neutral
compound, exhibited a slight inhibitory effect (krel = 0.74, see
footnote in Table 1), but only upon preincubation with the
enzyme. It should be mentioned that all compounds in Table 1
were additionally checked under conditions of preincubation with
ADC (typically 1 hour, room temperature); however, no differ-
ences with respect to the inhibition potential were noted except for
D-tagatose (I4). The fact that I5, which had emerged as another
hit from the chemoinformativs study, showed no detectable
inhibitory effect emphasizes the need for complementary compu-
tational and experimental studies.
Based on the crystal structure [6], the affinity of molecules to the
active site of ADC was postulated to be dominated by two
moieties: the pyruvoyl group and the Arg54 residue. All newly
tested compounds were selected upon ensuring both a direct
interaction with Arg54 residue, while excluding contact with the
MtbADC pyruvoyl group [9]. Our data clearly reveal that the
inhibitory potential of the tested ligands is, actually, directly
dependent on the number of carboxylate groups present. It
Figure 3. Kinetic monitoring of ADC activity carried out using
1 mM L-aspartate and 3 mM enzyme. The different points
correspond to conversion percentages of the individual 1H NMR
spectra taken at increasing reaction times after initiation of the reaction
in D2O at 25uC. Percentage of product formation and substrate
depletion is represented by filled and empty circles, respectively. The
percentage of product and substrate after 30 min of the reaction in the
presence of D-tartrate is represented by filled and empty squares,
respectively.
doi:10.1371/journal.pone.0045947.g003
Table 1. Relative inhibitory effects of selected known and newly tested compounds against ADC.[a]
Entry Compound Conversion %[b] krel
[c] Classification
Ref. None 50 1.00 reference
Reported compounds [10]
K1 oxaloacetate 0[d] 0.00[d] very strong
K2 b-hydroxyaspartate 18 0.36 strong
K3 L-glutamate 20 0.40 strong
K4 L-cysteate 20 0.40 strong
K5 succinate 32 0.64 moderate
K6 L-serine 45 0.90 weak
K7 D-serine 48 0.96 insignificant
Newly tested compounds
I1 D-tartrate 18 0.36 strong
I2 L-tartrate 19 0.38 strong
I3 2,4-dihydroxypyrimidine-5-carboxylate 27 0.54 moderate
I4 D-tagatose 45[e] 0.90[e] weak
I5 (4S)-1,3-thiazolidin-3-ium-4-carboxylate 48 0.96 insignificant
I6 a-D-arabinopyranose 48 0.96 insignificant
I7 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one 48 0.96 insignificant
[a]The measurements were performed using 1 mM L-aspartate, 3 mM ADC, and 1 mM compound (potential inhibitor) in D2O at 25uC.
[b]The conversion percentage corresponds to the product formed by integration of the 1H NMR signals corresponding to substrate and product of the enzymatic
reaction after ca. 30 min upon addition of the enzyme. The time was adjusted to correspond to 50% conversion in the absence of inhibitor (reference). The absolute
values were averaged from at least two independent assays.
[c]The relative inhibitory effect, krel, was calculated as the ratio of the conversion percentages in the presence and absence of compound.
[d]While full inhibition was also observed when using double the enzyme concentration, i.e., 6 mM, only a small nhibitory effect could be detected (krel = 0.9) when the
assay was performed with 100 mM oxaloacetate, i.e., at a 10-fold lower inhibitor concentration.
[e]A smaller krel value of 0.74, suggesting moderate inhibition, was observed upon preincubation with ADC for 1 h at ambient temperature.
doi:10.1371/journal.pone.0045947.t001
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transpires that in the absence of any ligand interaction with
pyruvoyl, Arg54 presides over the active-site binding, which
corroborates that this well conserved residue has a fundamental
role in substrate specificity, namely by forming a salt bridge with
the b-carboxylate of L-aspartate [21].
Apart from compounds I1 and I3–I7, which had been identified
as putative inhibitors via virtual screening, we have also included
L-tartrate (I2), the enantiomer of I1, in our experiments. To our
surprise, an essentially identical, strong inhibitory effect as that for
the D-isomer was observed (krel = 0.38). The D-/L-tartrate
example suggests that the chirality of the ligands has no large
influence on their binding to the ADC active site, but that the
binding is mainly driven by less specific electrostatic interactions.
Conclusions
In order to counter multi-drug resistance, attenuate Mycobacte-
rium tuberculosis’s virulence, and expedite recovery or prolong the
survival of patients, additional drugs, in combination with
conventional antibiotics, are continuously needed. The develop-
ment of convenient and easily accessible enzymatic assays
combined with drug validation tools are, thus, a compulsory
requirement. In this work, we were able to monitor b-alanine
formation from L-aspartate during enzymatic conversion via 1H
NMR. This is the first assay reported for ADC, which allows one
to accurately monitor the related biocatalytic reaction in a direct
and label-free fashion. The functionality of the assay was
demonstrated by its use in experimental screening for ADC
inhibitors, which allowed the validation of three computationally
identified inhibitors against the Mycobacterium tuberculosis L-aspar-
tate a-decarboxylase enzyme.
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